Yuhong Xu

Company: Highfield Biopharmaceuticals

Job title: Chief Scientific Officer

Seminars:

Advancing Antibody Fragment-Lipid Conjugates for Greater Therapeutic Targeting 11:30 am

Explore the development of antibody fragment-lipid conjugates, which utilise antibody fragments instead of full antibodies to create specialised lipid formulations. This flexibility allows for mix-and-match combinations tailored to specific therapeutic needs Review the current pipeline, including the trastuzumab Fab-lipid conjugate TL01 and several different product formats under development based on it Delve into the creation…Read more

day: Conference Day 2